Circulating Tumor DNA as Biomarkers for Cancer Detection.
Circulating Tumor DNA as Biomarkers for Cancer Detection.
复制标题
DOI：
10.1016/j.gpb.2016.12.004
复制
发表时间：
2017-04
期刊：
影响因子：
--
通讯作者：
Sun Y
中科院分区：
文献类型：
--
作者：
Han X;Wang J;Sun Y
癌症患者循环肿瘤DNA(CtDNA)的检测是癌症精准医学ctDNA的重要组成部分。与传统的物理和生化方法相比，基于血液的ctDNA检测为癌症的诊断、预后判断和指导治疗提供了一种非侵入性和简便易行的方法。虽然目前对这一主题的研究正在进行中，但由于ctDNA作为血液生物标志物在癌症早期诊断和治疗中的巨大潜力，ctDNA在各种类型癌症中的临床翻译已经引起了人们的极大关注。CtDNA的检测和跟踪主要基于与肿瘤相关的遗传和表观遗传变化。本文对现有的ctDNA检测方法进行了综述，并对具有代表性的检测方法进行了描述。我们还讨论了目前癌症患者对ctDNA的理解，以及它们作为潜在的临床生物标志物的可用性。考虑到在准确检测特定的无细胞核酸方面取得的进展和面临的挑战，ctDNA有望作为癌症患者的生物标志物，在其广泛临床应用之前还需要进一步的验证。
Detection of circulating tumor DNAs (ctDNAs) in cancer patients is an important component of cancer precision medicine ctDNAs. Compared to the traditional physical and biochemical methods, blood-based ctDNA detection offers a non-invasive and easily accessible way for cancer diagnosis, prognostic determination, and guidance for treatment. While studies on this topic are currently underway, clinical translation of ctDNA detection in various types of cancers has been attracting much attention, due to the great potential of ctDNA as blood-based biomarkers for early diagnosis and treatment of cancers. ctDNAs are detected and tracked primarily based on tumor-related genetic and epigenetic alterations. In this article, we reviewed the available studies on ctDNA detection and described the representative methods. We also discussed the current understanding of ctDNAs in cancer patients and their availability as potential biomarkers for clinical purposes. Considering the progress made and challenges involved in accurate detection of specific cell-free nucleic acids, ctDNAs hold promise to serve as biomarkers for cancer patients, and further validation is needed prior to their broad clinical use.